Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ligand Pharmaceuticals (LGNYZ) Return on Capital Employed (2016 - 2025)

Historic Return on Capital Employed for Ligand Pharmaceuticals (LGNYZ) over the last 15 years, with Q3 2025 value amounting to 0.01%.

  • Ligand Pharmaceuticals' Return on Capital Employed rose 300.0% to 0.01% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.01%, marking a year-over-year increase of 300.0%. This contributed to the annual value of 0.03% for FY2024, which is 400.0% down from last year.
  • Ligand Pharmaceuticals' Return on Capital Employed amounted to 0.01% in Q3 2025, which was up 300.0% from 0.04% recorded in Q2 2025.
  • Ligand Pharmaceuticals' 5-year Return on Capital Employed high stood at 0.09% for Q1 2022, and its period low was 0.07% during Q1 2025.
  • For the 5-year period, Ligand Pharmaceuticals' Return on Capital Employed averaged around 0.02%, with its median value being 0.01% (2025).
  • As far as peak fluctuations go, Ligand Pharmaceuticals' Return on Capital Employed surged by 700bps in 2021, and later tumbled by -800bps in 2022.
  • Quarter analysis of 5 years shows Ligand Pharmaceuticals' Return on Capital Employed stood at 0.08% in 2021, then crashed by -95bps to 0.0% in 2022, then soared by 317bps to 0.02% in 2023, then tumbled by -258bps to 0.02% in 2024, then skyrocketed by 160bps to 0.01% in 2025.
  • Its Return on Capital Employed was 0.01% in Q3 2025, compared to 0.04% in Q2 2025 and 0.07% in Q1 2025.